IMV - IMV STOCK NEWS

IMV announced the results of its annual meeting of shareholders held on June 18, 2021. All resolutions, including the election of directors, were approved. Andrew Sheldon received 61.96% of votes for his position, while Michael Bailey secured 75.49%. The appointment of PricewaterhouseCoopers as the independent auditor was also approved. Additionally, shareholders consented to amendments to the stock option plan, transitioning it to a rolling plan. Forward-looking statements regarding the FDA approval of maveropepimut-S and related studies were highlighted, urging caution on reliance due to inherent risks.

IMV Inc. (NASDAQ: IMV) announced the appointment of Jeremy R. Graff, Ph.D., as Chief Scientific Officer, effective June 14, 2021. Dr. Graff has over 20 years in oncology research and has held leadership roles at HiberCell and Biothera Pharmaceuticals. His expertise is expected to enhance IMV's clinical development of its lead drug candidate, maveropepimut-S. Additionally, Stanley Frankel, M.D., joins as a clinical advisor to support development in diffuse large B-cell lymphoma and advanced ovarian cancer, contributing significant experience from Bristol-Myers Squibb.

IMV Inc. (Nasdaq: IMV), a clinical stage immuno-oncology company, announced participation in two investor conferences. The Sachs and Associates panel will feature CEO Fred Ors on May 19, 2021, at 2:50 p.m. EDT, requiring registration. Additionally, the Family Office Investor Event will take place on the same day at 10:00 a.m. EDT. A video presentation from the latter event will be available on IMV's website. IMV focuses on innovative immunotherapies, including Maveropepimut-S for advanced ovarian cancer and a COVID-19 vaccine.

IMV Inc. reported its Q1 2021 financial and operational results, highlighting a net loss of $7 million ($0.10 per share), a slight decrease from $7.2 million in Q1 2020. As of March 31, 2021, cash reserves stood at $30.5 million, expected to fund operations until Q1 2022. Key developments include the initiation of a Phase 2B trial for maveropepimut-S in DLBCL and a Phase 1 study for DPX-SurMAGE in bladder cancer, supported by a C$1.8 million grant. New board members with expertise in immuno-oncology were appointed, while the company expects a clinical update on trials later this year.

IMV Inc. has appointed Dr. Michael Kalos to its board of directors, effective immediately. An expert in T cell therapy with over 25 years of experience, Dr. Kalos previously held positions at Janssen and Eli Lilly, focusing on immuno-oncology. His expertise is expected to enhance IMV's clinical development, particularly for its lead candidate, maveropepimut-S. Additionally, James Hall will retire from the board after over 11 years of service, marking a significant leadership change. IMV aims to broaden its pipeline of immunotherapy candidates in the oncology sector.

IMV Inc. (Nasdaq: IMV) is initiating a clinical study of its lead compound, maveropepimut-S, for treating hormone receptor positive/HER2-negative breast cancer. Conducted at the Providence Cancer Institute, the Phase 1B trial will evaluate the drug's safety in combination with an aromatase inhibitor and potential additional treatments. Maveropepimut-S aims to improve treatment responses in patients resistant to traditional therapies.

IMV's innovative T-cell therapy, already showing promise in other cancer types, seeks to enhance immune responses against survivin, a tumor-associated antigen.

IMV Inc. (Nasdaq: IMV), a clinical stage immuno-oncology company, announced its participation in the 2021 Bloom Burton & Co. Healthcare Investor Virtual Conference on April 20-21, 2021. The presentation is scheduled for April 20 at 4:00 p.m. ET, which will be accessible via a live webcast on IMV’s website and archived afterwards. IMV focuses on innovative cancer immunotherapies using its proprietary delivery platform, DPX, including its lead candidate, Maveropepimut-S, aimed at advanced ovarian cancer and COVID-19 vaccination.

IMV Inc. (Nasdaq: IMV) has partnered with Merck to initiate a Phase 2B clinical trial evaluating maveropepimut-S (DPX-Survivac) with KEYTRUDA^® in patients with recurrent/refractory diffuse large B cell lymphoma. Following FDA feedback, the trial will assess up to 150 subjects, focusing on Objective Response Rate (ORR) as a primary endpoint. IMV aims to validate SPiReL study findings regarding PD-L1 as a potential biomarker. This collaboration represents a strategic advancement in IMV's development strategy targeting previously difficult-to-treat cancers.

IMV Inc. (NASDAQ: IMV) has announced the appointment of Kyle Kuvalanka to its Board of Directors, effective April 1, 2021. With over 20 years of biopharmaceutical experience, Kuvalanka's expertise in strategic collaborations and financing will be valuable as IMV advances its lead candidate, maveropepimut-S, in Phase 2 trials for various cancers. Concurrently, Wayne Pisano is retiring after a decade on the board. IMV aims to leverage Kuvalanka's skills to broaden its immunotherapy pipeline and navigate corporate strategies during this critical growth phase.